Want to see GB:IDHC full AI Analyst Report?
IDHC Stock Chart & Stats
$0.63
$0.02(4.13%)
At close: 4:00 PM EST
$0.63
$0.02(4.13%)
Day’s Range― - ―
52-Week Range$0.32 - $0.84
Previous CloseN/A
Volume5.52K
Average Volume (3M)148.95K
Market Cap
$296.48M
Enterprise Value$16.81B
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)11.6
Beta0.97
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.39%
Share Statistics
EPS (TTM)1.88
Shares Outstanding581,326,300
10 Day Avg. Volume181,236
30 Day Avg. Volume148,946
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)6.10
Price to Sales (P/S)2.63
P/FCF Ratio14.92
Enterprise Value/Market Cap56.71
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit6.12
Enterprise Value/Ebitda8.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue MomentumSustained double-digit top-line growth (+16.1% in 2025) indicates durable demand for diagnostics services and improved market penetration. That revenue momentum supports scale benefits, recurring test volumes, and long-term capacity investments that underpin structural earnings growth.
High Operating ProfitabilityVery strong operating margins (EBIT ~29.6%, EBITDA ~36.8%) reflect a high-margin service mix and operational leverage typical in diagnostics. Durable margin levels provide capacity to reinvest in labs, fund R&D or expansion, and absorb cost shocks without immediate profit erosion.
Improving Leverage & Strong ROEAn improving debt-to-equity ratio (~0.48) together with very strong ROE (~37.3%) signals efficient capital deployment and stronger balance sheet resilience. This combination supports strategic investment, credit access, and long-term shareholder returns even as the business scales.
Bears Say
Rising Absolute DebtAlthough leverage ratios improved, rising absolute debt increases interest and refinancing exposure. If revenue growth or margins slow, higher nominal debt can constrain financial flexibility, limit capital allocation choices, and elevate risk in a higher-rate environment.
Inconsistent Cash ConversionVariable cash conversion—FCF ~73% of net income in 2025 and a negative FCF year in 2022—signals working capital or capex swings. This inconsistency can undermine the reliability of reported earnings to fund dividends, deleveraging or capex, raising structural funding risk.
Margin Softening Vs Peak YearsNet margin retreat from earlier peak years and a dip versus 2024 suggest cost pressures or adverse volume/mix trends. If structural, continued margin erosion would reduce free cash generation, weaken returns on capital, and constrain reinvestment or debt servicing capacity.
Integrated Diagnostics Holdings News
IDHC FAQ
What was Integrated Diagnostics Holdings PLC’s price range in the past 12 months?
Integrated Diagnostics Holdings PLC lowest share price was $0.32 and its highest was $0.83 in the past 12 months.
What is Integrated Diagnostics Holdings PLC’s market cap?
Integrated Diagnostics Holdings PLC’s market cap is $296.48M.
When is Integrated Diagnostics Holdings PLC’s upcoming earnings report date?
Integrated Diagnostics Holdings PLC’s upcoming earnings report date is Aug 27, 2026 which is in 56 days.
How were Integrated Diagnostics Holdings PLC’s earnings last quarter?
Currently, no data Available
Is Integrated Diagnostics Holdings PLC overvalued?
According to Wall Street analysts Integrated Diagnostics Holdings PLC’s price is currently Overvalued.
Does Integrated Diagnostics Holdings PLC pay dividends?
Integrated Diagnostics Holdings PLC pays a Annually dividend of $0.009 which represents an annual dividend yield of 2.39%. See more information on Integrated Diagnostics Holdings PLC dividends here
What is Integrated Diagnostics Holdings PLC’s EPS estimate?
Integrated Diagnostics Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated Diagnostics Holdings PLC have?
Integrated Diagnostics Holdings PLC has 581,326,300 shares outstanding.
What happened to Integrated Diagnostics Holdings PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Integrated Diagnostics Holdings PLC?
Currently, no hedge funds are holding shares in GB:IDHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integrated Diagnostics Holdings Stock Smart Score
Company Description
Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 distinct diagnostic examinations, spanning specialized fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. Geographically, IDHC has established operations across Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, its infrastructure included an extensive network of 452 laboratory branches. The organization was founded in 1979 and maintains its corporate headquarters in Saint Helier, Jersey.
Technical Analysis
Bioventix
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Abingdon Health PLC
―
Options Prices
Currently, No data available
---